were initially placed in the light chamber and 10 s later the door between compartments was opened. When mice entered the dark compartment, the door automatically closed and an electrical foot shock (0.1 mA/10 g body weight) for a time period of 2 s was delivered through the stainless steel rods (one trial training). Ten mice were used per treatment. For acute treatment experiment, mice received acteoside (0.1, 1.0, 2.5 mg/kg body weight) by oral administration 120 min before the training trial. After 90 min, amnesia was induced in mice with scopolamine (1.0 mg/kg body weight, dissolved in 0.1% DMSO) given subcutaneously. For prolonged treatment experiment, mice were orally treated with acteoside (0.1 mg/kg body weight/d) for 10 d. Twenty-four hours after the training trial, the mice were again placed in the light compartment. The latency time to enter the dark compartment was measured. If the mice did not enter the dark compartment within 180 s, we concluded that the mice had memorized the passive avoidance training after one training trial.
Morris Water Maze Test A spatial memory test was performed by the method of Morris 13) with minor modification described in our previous reports. 11, 12) The Morris water maze is a white circular pool (90 cm in diameter and 45 cm in height) with a featureless inner surface. The circular pool was filled to a height of 30 cm with water (20Ϯ1°C), in which 500 ml of milk was mixed. The pool was divided into four quadrants of equal area. A white platform (6 cm in diameter and 29 cm in height) was centered in one of the four quadrants of the pool and submerged 1 cm below the water surface so that it was invisible at water level. In the water maze experiments, the first day of the experiment was dedicated to swimming training for 60 s in the absence of the platform. In the following days, the mice were given two trial sessions each day for four consecutive days. During each trial, the escape latencies of mice, as measured with a stopwatch, were recorded by the same experimenter. This parameter was averaged for each session of trials and for each mouse. Once the mouse located the platform, it was permitted to remain on it for 10 s. If the mouse did not locate the platform within 120 s, it was placed on the platform for 10 s and then removed from the pool. The mouse was given two daily trials for 4 d with an inter-trial interval of 20 min. The point of entry of the mouse into the pool and the location of the platform for escape remained unchanged between trials 1 and 2 but was changed on each day. The decrease in escape latency from day to day in trial 1 represents long-term memory or reference memory while that from trial 1 to trial 2, represents short-term memory or working memory. Ten mice were used per treatment. For prolonged treatment experiment, mice were pretreated with acteoside (1.0 mg/kg body weight/d, p.o.) for 10 d. After 90 min, amnesia was induced in mice with scopolamine (1.0 mg/kg body weight, dissolved in 0.1% DMSO) given subcutaneous. All mice were tested for spatial memory 30 min after the administration of scopolamine Statistical Analysis All data were expressed as meanϮ S.D. Passive avoidance latencies were analyzed by one-way ANOVA. Morris water maze latencies were analyzed by twoway ANOVA with the day as one variable and the treatment as a second. The data were considered to be significant statistically if the probability had a value of 0.05 or less.
RESULTS AND DISCUSSION
The present study has been performed in an attempt to evaluate the cognitive-enhancing activity of the major constituent, acteoside isolated from the leaves and twigs of C. dichotoma 5) for the possibility of preventing and/or treating memory deficits such as those seen in AD.
We examined whether acteoside mitigated the scopolamine-induced memory deficits through the passive avoidance test. The step-through latency of the scopolaminetreated (1.0 mg/kg body weight s.c.) group was significantly shorter than that of the 0.5% carboxymethylcellulose (CMC)-saline-treated control group. The shorter stepthrough latency induced by scopolamine was significantly reversed by acteoside (1.0-2.5 mg/kg body weight p.o.) ( Table  1) . It was also found that escape latencies of acteoside alonetreated groups of each dose were not significantly different from that of control group. Donepezil, an AChE inhibitor and most widely used treatment for AD, was used as a positive control.
14) Donepezil was reported to exhibit a bellshaped dose-response curve (0.01-10 mg/kg body weight p.o.) in passive avoidance tests using scopolamine (2.0 mg/kg body weight i.p.)-induced amnesic rats and restore the stepthrough latency by about 60.8% at a dose of 0.1 mg/kg body weight as compared to the saline-treated control group. 19) Consistent with this result, donepezil at a dose of 0.1 mg/kg body weight (p.o.) restored the step-through latency by 45.6% as compared to the 0.5% CMC-saline treated control group in the passive avoidance test in our present study. Considering the cognition-enhancing activity of donepezil, it seems that the potency of acteoside is comparable to that of donepezil. Next we tested the effect of the prolonged treatment of acteoside on passisve avoidance test. Daily oral treatments with acteoside (0.1 mg/kg body weight) for 10 d produced no significant effect on body weight compared to the vehicle group. Animals appeared to behave normally in their home cage and test environments. In contrast with the result of acute treatment at the dose of 0.1 mg/kg body weight, prolonged treatment of acteoside (0.1 mg/kg body weight) significantly improved the memory deficit in mice with amnesia induced by scopolamine (Table 2) .
We examined whether acteoside affected working or reference memory using the Morris water maze, a test that can evaluate spatial memory. However, acute treatment of acteoside 1.0 mg/kg body weight did not significantly antagonize the effect of scopolamine on the escape latency in the test period (data not shown). The once daily oral treatment with acteoside (1.0 mg/kg body weight, p.o.) for ten days on spatial memory was also investigated in the Morris water maze test. Animals in the saline-treated control group rapidly learned the location of the platform. This was demonstrated by exhibiting a reduction in swimming times from the first to the second trial on day 1 and by reaching stable latencies at day 2 ( Fig. 2A) . Furthermore, we found the swimming pathway required to find the submerged platform was simplified in groups given saline (data not shown). The shortened swimming distance was well correlated with the decrease of swimming time. Acteoside alone-treated group also showed similar behavioral result to that of control group. By contrast, in the scopolamine-treated group (1.0 mg/kg body weight, s.c.), a characteristic swimming behavior, consisting of circling around the pool, was observed; the swimming times in trials 1 and 2 remained unchanged throughout the entire 4-d testing period (Fig. 2B) . Prolonged treatment of acteoside (1.0 mg/kg body weight, p.o.) significantly antagonized the effect of scopolamine on swimming time in the testing period (Fig. 2C) . In the acteoside-treated mice, the latencies for trial 2 were significantly lower than that in trial 1. Furthermore, acteoside treatment tended to decrease the swimming time in each of the 1st trials over the 4 d (Fig. 2C ) and also simplified the swimming pathway, which was well correlated with the degree of the shortened swimming time. The swimming times in groups control or scopolamine with or without 
Experimental treatment
Step through latency (s) (% of control) Scopolamine interferes with memory and cognitive function and subsequently causes similar degrees of impairment in both reference and working memory in the Morris water maze test.
16) The paradigm used in the Morris water maze test enables the simultaneous analysis of distinctions between working and reference memory processes. 16, 17) In this study, the 0.5% CMC-saline-treated group exhibited that both working and reference memories were being formed. In contrast, in the scopolamine-treated group, neither working nor reference memory was exhibited. Prolonged treatment of acteoside (1.0 mg/kg body weight, p.o.) significantly reduced the deficits in working and reference memories induced by scopolamine (Fig. 2C) . From the second day of testing, acteoside-treated group remarkably improved the deficit in working memory induced by scopolamine. In addition, acteoside-treated group exhibited significant gradual improvement in reference memory.
Although acteoside exerted its remarkable cognitive-enhancing action on memory deficits induced by a muscarinic antagonist, scopolamine, in experiment mice, acteoside did not show a significant effect on AChE activity (data not shown). Therefore, we think that acteoside could have a direct/indirect action as cholinergic agonist or a modulatory action on cholinergic transmission, because acteoside attenuated muscarinic antagonist-induced memory impairments. Recently, scopolamine is additionally known to trigger the production of reactive oxygen species (ROS), inducing free radical injury. 18, 19) El-Sherbiny et al. reported that memory impairment induced by acute administration of scopolamine in rats is associated with altered brain oxidative stress status. 20) Several natural products with antioxidant proprieties have been reverting the cognitive impairment in aged rats. [19] [20] [21] [22] [23] Therefore, the anti-oxidative effect of acteoside can also be suggested as possible mechanisms for its cognitive-enhancing activity.
In conclusion, based on the results of passive avoidance and the Morris water maze tests using mice with amnesia induced by scopolamine, we found that acteoside had remarkable cognitive-enhancing activity. Recently, natural products and/or such synthetically-developed active components as galanthamine and huperzine A have received approval for the treatment of AD or have been under clinical study. 24, 25) Natural compounds such as acteoside that exert anti-amnesic activity in vivo might offer a useful therapeutic choice in the treatment of AD.
